Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)
about
A pill for HIV prevention: déjà vu all over again?Antiretroviral drugs-based HIV prevention methods: what impact on the HIV epidemic?Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesHIV treatment as prevention: contradictory perspectives from dynamic mathematical modelsPrevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009)Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling studyAnalytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectivenessHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactChallenges for HIV pre-exposure prophylaxis among men who have sex with men in the United States.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.What do mathematical models tell us about the emergence and spread of drug-resistant HIV?"Why should I take drugs for your infection?": outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria.Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.How could preventive therapy affect the prevalence of drug resistance? Causes and consequences.Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistancePre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?Frequency of HIV testing among gay and bisexual men in the UK: implications for HIV prevention.Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics.The Promise of Antiretrovirals for HIV Prevention.Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical TrialsRisk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study.Healthcare providers' knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection.Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?New insights into the evolutionary rate of HIV-1 at the within-host and epidemiological levelsHIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials
P2860
Q26824606-94AF7A7D-5D92-4B77-A00B-2A69C74C15D3Q26825761-F9465E1F-A459-4DCE-BE54-E16E8536A184Q26853055-88FCADD7-A704-43A5-81F0-2E1AF3723E9FQ27023352-5B2B5023-3DDD-45CF-B1DB-636488947D61Q28080917-AC13C296-0B1E-4FE2-92EA-AC7E9D9902F0Q28486101-A6B10C8F-734A-44ED-BC2B-97517D0C6A7CQ28488157-F6D9C3BE-8F1E-41D6-B4AD-0ECE925746D2Q28535414-D520275D-487F-4A57-9F2C-25AE5F3496FFQ28552455-9C83BE3B-1B22-42F3-9998-388A9727C322Q34395187-9A9D1446-B2D0-4414-A0D6-6040AA57C1C4Q34573789-DDFF06BD-7CBE-40F0-9572-1A952ACD97BCQ34989198-3642BEF9-1C55-46F8-84AB-28FEC7D79E64Q35496515-71021434-D3A1-4D6A-983B-78C31F61F733Q35575958-365D2BD7-65DF-4916-8AD8-390757AACFCFQ35583501-DCC3A297-CE37-41A0-9E86-F4EA037CF851Q35619584-DCF3286A-52B0-42D4-8C3E-9D2A2CC3D738Q35636514-DDD8D51F-4C0B-4647-B4F2-0C104483B76CQ36669337-BABD10D5-77DB-4166-9C97-0F86227CCDC1Q37146567-0DD2FAA7-1153-420C-B36A-F1CD92558EE9Q37261781-A82AF67F-39A6-4E1A-B5E1-808FA8A1C86BQ37409926-47438B37-E5AE-4AAE-91D0-2DB10AC017D8Q37511883-4B3ABBF8-138D-4F7D-B53A-8E293CA4B12CQ38256787-31E41EBA-AC58-4BB0-817A-DC745B1268E9Q39909478-66C8B25B-50EC-44B9-99FB-5FEA1A40D604Q40186272-EE11D4A3-BEC1-46A8-941E-CC60C1039F02Q40739990-1FF67992-AD25-425E-8952-F019B54F94CDQ52612456-BE2394E8-C4CF-4513-A550-E2E16A6164BAQ56880081-E9D64F00-13CE-4541-B641-C067BFF02123Q57207278-37BD45D4-D27D-4DA3-8CFA-FB71B655562C
P2860
Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@ast
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@en
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@nl
type
label
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@ast
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@en
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@nl
prefLabel
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@ast
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@en
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@nl
P2093
P2860
P3181
P1433
P1476
Factors influencing the emerge ...... re-exposure prophylaxis (PrEP)
@en
P2093
Arthur W Wetzel
Gregory Hood
John W Mellors
Ume L Abbas
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0018165
P407
P577
2011-04-15T00:00:00Z